Abstract
Multiple sclerosis (MS), although well-described clinically and pathologically for over 120 years, is only now poised for a new era of improved therapy brought about primarily by findings obtained from clinical research. Over the past 12 years, various investigations of new treatments have not only identified effective agents but have provided unexpected new insights into the basic mechanisms of disease activity in MS. The combination of carefully designed and conducted clinical trials, coupled with serial MRI studies of the brain, has allowed us to determine the therapeutic benefit of one and perhaps two treatments with low risk and toxicity which are likely to be available to the general MS community within 6 to 24 months.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
B.G. Weinshenker, B. Bass, G.P.A. Rice, J. Noseworthy, W. Carriere, et al, The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course, Brain 112: 1419–1428 (1989).
The IFN-Multiple Sclerosis Study Group, Interferon-beta 1 B is effective in relapsing-remitting multiple sclerosis: Clinical results of a multicenter, randomized, double blind, placebo controlled trial, Neurol. 43: in press (1993).
A. Isaacs, J. Lindenmann, Virus interference, I. The interferon, Proceedings of the Royal Society of London (Biology) 147: 258–267 (1957).
H.S. Panitch, Interferons in multiple sclerosis. A review of the evidence, Drugs. 44(6): 946–962 (1992).
P.A. Neighbor, A.E. Miller, B.R. Bloom, Interferon responses of leucocytes in multiple sclerosis, Neurol. 31: 561–566 (1981).
S. Dhib-Jalbut, D.E. McFarlin, Immunology of multiple sclerosis, Ann Allergy. 64: 433–444 (1989).
H.S. Panitch, J.S. Folus, K.P. Johnson, Recombinant beta interferon inhibits gamma interferon production in multiple sclerosis, Abstract, Ann Neurol. 22: 139 (1987a).
A. Noronha, A. Toscas, M.A. Jensen, Interferon beta augments suppressor cell function in multiple sclerosis, Ann Neurol. 27: 207–210 (1990).
H.S. Panitch, J.S. Folus, K.P. Johnson, Activated suppressor cells inhibit synthesis of interferon-―in patients with multiple sclerosis patients and normal subjects, Abstract, J Neuroimmunol. In press (1992b).
R. Arnon, Experimental allergic encephalomyelitis-susceptibility and suppression, Immunol. Rev. 55: 5–30 (1981).
M.B. Bornstein, A. Miller, S. Slagle et al, A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosisA pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis, N Engl J Med. 317: 408–414 (1987).
M.B. Bornstein, K.P. Johnson, Treatment of multiple sclerosis with Copolymer I, in: “Handbook of Multiple Sclerosis,” S.D. Cook, ed., Marcel Dekker, Inc., New York and Basel (1990).
M.B. Bornstein, A. Miller, S. Slagle et al, A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis, Neurol. 41: 533–539 (1991).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media New York
About this chapter
Cite this chapter
Johnson, K.P., Panitch, H.S. (1994). Interferon and Copolymer I Treatment in Multiple Sclerosis: Clinical and Pathobiological Implications. In: Salvati, S. (eds) A Multidisciplinary Approach to Myelin Diseases II. NATO ASI Series, vol 258. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2435-9_24
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2435-9_24
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6034-6
Online ISBN: 978-1-4615-2435-9
eBook Packages: Springer Book Archive